Ly93

Research use only, not for human use.

Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor (IC50: 91 nM) used for studying atherosclerosis.

Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM.

——

Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice.Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice.Animal Model:C57BL/6J mice.Dosage:100 mg/kg.Administration:I.G. (gavage) once daily for 7 days.Result:Significantly decreased the plasma SM levels compared with vehicle group.Animal Model:ApoE KO mice (eight-week-old).Dosage:12.5 or 40 mg/kg.Administration:I.G. (gavage) once daily.Result:The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group.

——

Others

Other Targets

Others

——

——

1883528-69-5

332.4

C21H20N2O2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (752.11 mM; Ultrasonic )

CCc1ccccc1COc1ccccc1C(=O)Nc1cccnc1

——

(-20℃)

With Ice Pack

≥ 2 years